Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness by Abdeen, Sanofar et al.
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating 
African sleeping sickness. 
Sanofar Abdeen,a Nilshad Salim,a Najiba Mammadova,a† Corey M. Summers,a‡ Karen Goldsmith-
Pestana,b Diane McMahon-Pratt,b Peter G. Schultz,c Arthur L. Horwich,d Eli Chapman,e and Steven M. 
Johnsona* 
a Indiana University, School of Medicine, Department of Biochemistry and Molecular Biology, 635 
Barnhill Dr., Indianapolis, IN, 46202 
b Yale School of Public Health, Department of Epidemiology of Microbial Diseases, 60 College St., 
New Haven, CT, 06520 
c The Scripps Research Institute, Department of Chemistry, 10550 North Torrey Pines Rd., La Jolla, CA 
92037 
d HHMI, Department of Genetics, Yale School of Medicine, Boyer Center for Molecular Medicine, 295 
Congress Ave., New Haven, CT, 06510 
e The University of Arizona, College of Pharmacy, Department of Pharmacology and Toxicology, 1703 
E. Mabel St., Tucson, AZ 85721 
Present addresses: 
† Department of Genetics, Development and Cell Biology, Iowa State University, 1210 Molecular 
Biology Building, Pannel Dr, Ames, IA 50011 
‡ Department of Kinesiology, Iowa State University, 235 Barbara E. Forker Building, Beach Rd, Ames, 
IA 50011 
*Correspondence: johnstm@iu.edu, Tel: 317-274-2458, Fax: 317-274-4686
KEYWORDS: GroEL, GroES, HSP60, HSP10, molecular chaperone, chaperonin, proteostasis, small 
molecule inhibitors, antibiotics, parasites, Trypanosoma brucei, African Sleeping Sickness. 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as: 
Abdeen, S., Salim, N., Mammadova, N., Summers, C. M., Goldsmith-Pestana, K., McMahon-Pratt, D., … Johnson, S. M. 
(2016). Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping 




Trypanosoma brucei are protozoan parasites that cause African sleeping sickness in humans 
(also known as Human African Trypanosomiasis – HAT).  Without treatment, T. brucei infections are 
fatal.  There is an urgent need for new therapeutic strategies as current drugs are toxic, have complex 
treatment regimens, and are becoming less effective owing to rising antibiotic resistance in parasites.  
We hypothesize that targeting the HSP60/10 chaperonin systems in T. brucei is a viable anti-
trypanosomal strategy as parasites rely on these stress response elements for their development and 
survival.  We recently discovered several hundred inhibitors of the prototypical HSP60/10 chaperonin 
system from E. coli, termed GroEL/ES.  One of the most potent GroEL/ES inhibitors we discovered was 
compound 1.  While examining the PubChem database, we found that a related analog, 2e-p, exhibited 
cytotoxicity to Leishmania major promastigotes, which are trypanosomatids highly related to 
Trypanosoma brucei.  Through initial counter-screening, we found that compounds 1 and 2e-p were also 
cytotoxic to Trypanosoma brucei parasites (EC50 = 7.9 and 3.1 M, respectively).  These encouraging 
initial results prompted us to develop a library of inhibitor analogs and examine their anti-parasitic 
potential in vitro.  Of the 49 new chaperonin inhibitors developed, 39% exhibit greater cytotoxicity to T. 
brucei parasites than parent compound 1.  While many analogs exhibit moderate cytotoxicity to human 
liver and kidney cells, we identified molecular substructures to pursue for further medicinal chemistry 
optimization to increase the therapeutic windows of this novel class of chaperonin-targeting anti-
parasitic candidates.  An intriguing finding from this study is that suramin, the first-line drug for treating 
early stage T. brucei infections, is also a potent inhibitor of GroEL/ES and HSP60/10 chaperonin 




Parasitic infections, such as those that cause African sleeping sickness (also known as Human 
African Trypanosomiasis – HAT), Chagas disease, leishmaniasis, toxoplasmosis, and malaria, cause 
significant morbidity and mortality worldwide.  While antibiotic resistance continues to mount, a 
pressing issue is that some of these diseases have never benefited from adequate antibiotic availability in 
the first place.  Such is the case for HAT, which is caused by infection with the parasitic protozoa, 
Trypanosoma brucei.  Transmission of T. brucei between mammalian hosts occurs through an insect 
vector, the tsetse fly (genus Glossina).  HAT is endemic to the region between the Sahara and Kalahari 
deserts, where ~70 million people are at risk of contracting the disease.1-4  Around 10,000 new cases of 
HAT are reported each year, although the actual number is likely much higher owing to insufficient 
reporting.5  Two sub-species of parasites are responsible for HAT: T. brucei gambiense and T. brucei 
rhodesiense.  While the general symptoms of HAT are similar, the speed of disease progression differs 
markedly between the two organisms: T.b. gambiense causes a more gradual onset of symptoms over the 
course of months to years, while T.b. rhodesiense causes acute disease that progresses within weeks to 
months.5, 6  Without treatment, both infections are fatal.  Disease progression occurs in two stages.  The 
first is termed the early, haemolymphatic stage, where parasites enter and spread in the bloodstream, 
lymph nodes, and systemic organs.  Symptoms of this stage can include itching, fever, headaches, 
malaise, joint pains, and severe swelling of the lymph nodes.  After a variable time period (weeks for 
T.b. rhodesiense and months for T.b. gambiense), parasites cross the blood-brain barrier and enter the 
central nervous system.  Once this occurs, HAT is considered to be in the late, encephalitic stage, which 
is characterized by disruption of the sleep cycle and progressive mental deterioration leading to coma, 
systemic organ failure, and death. 
None of the current drugs (Figure 1) are ideal for treating HAT as they all suffer from varying 
pharmacological deficiencies.  While first line treatments of suramin (T.b. rhodesiense) or pentamidine 
(T.b. gambiense) are often effective for the early systemic stage of disease, they are ineffective against 
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the later CNS stage once parasites have crossed the blood-brain barrier.5  Eflornithine, nifurtimox, and 
melarsoprol can treat CNS-stage T.b. gambiense infection, but only melarsoprol is effective against T.b. 
rhodesiense.  Melarsoprol is itself toxic and leads to the death of ~5% of patients.5, 7, 8  These drugs also 
have poor oral bioavailability, which necessitates frequent IV and/or IM injections.  Unfortunately, no 
new drugs have been developed against T. brucei since the advent of eflornithine in the 1970s.  Due to 
associated toxicities, the complexity of treatment regimens, and the rise of resistance to current HAT 
therapies, there is an urgent need to develop safe, effective, and easily administered treatments.9  
Towards this goal, we are investigating modulating the protein homeostasis pathways of T. brucei as a 
viable antibiotic strategy. 
Figure 1.  Structures of drugs currently used to treat African sleeping sickness.  
 
 
Molecular chaperones are key modulators of protein homeostasis as they are essential in helping 
many proteins fold into their functional forms and assist with their degradation.10-12  HSP60/10 
chaperonins are unique members of the molecular chaperone family that are generally found in 
eukaryotic mitochondria and bacterial cytosol (also known as GroEL/ES).  Through a series of events 
driven by ATP binding and hydrolysis, unfolded substrate proteins are bound within the central cavity of 




































































a sequestered chamber.13-15  HSP60/10 chaperonins are viable antibiotic targets because cells rely on 
them to survive.16-19  Notably, many organisms have multiple HSP60 isoforms that they modulate to 
adapt to their environments.19-25  For instance, T. brucei have three HSP60 isoforms (Figure 2A).26, 27  
While studies have indicated that HSP60 is associated with the mitochondrial matrix, kinetoplast, and 
flagellar pocket of T. brucei, the distribution and function of each HSP60 isoform are not well 
characterized.25, 28-30  However, recent studies have identified that expression of the HSP60 isoforms 
vary depending on the life cycle stage of the parasite and that depletion of each single variant can result 
in decreased growth and/or survival (Figure 2B).26, 27  The HSP60.1 isoform appears to be the canonical 
chaperonin system in T. brucei since it is essential, while the 60.2 and 60.3 isoforms are not.26  This is 
further supported by the fact that only the HSP60.1 isoform contains the C-terminal GGM-repeat motif 
that is typically found in canonical chaperonin systems.23, 28, 31, 32  Collectively, these results suggest that 
T. brucei may be susceptible to HSP60-targeting antibiotics.  Targeting the HSP60/10 chaperonins for 
antibiotic development would be a unique polypharmacological strategy as one drug could potentially 
inhibit the three chaperonin isoforms and have the cascading effect of modulating hundreds of 
downstream proteins.  Thus, it may be difficult for T. brucei to develop resistance to such a broadly-
acting class of antibiotics.   
Figure 2.  A.  Homology comparison of the three T. brucei HSP60 isoforms to E. coli GroEL (left) and 
the canonical T. brucei HSP60.1 isoform (right).  Human mitochondrial HSP60 is also shown for 
comparison. AA = Amino Acids.  B.  Previous studies report that genetic knock-down of any of the 




Figure 3.  Compound 1 was an initial hit that emerged from our recent high-throughput screening for 
GroEL/ES inhibitors.33  Compound 2e-p is a related analog found in the PubChem database (CID 
#1098316) that has reported bioactivity in only 8 of the 285 assays it has been evaluated in.34  One assay 
that 2e-p is reported active in is against Leishmania major promastigotes, which are parasites closely 
related to Trypanosoma brucei.  Analogs of compound 2e-p under development herein retain the 
benzoxazole core, while exploring a variety of sulfonamide end-capping substructures (R).  Notes on 
compound nomenclature: i) the number corresponds to the alkyl or aryl group adjacent to the 
sulfonamide linker; ii) the letter corresponds to the substituent present on the phenyl group for the 
compound 2 series of analogs; and iii) o, m, and p correspond to ortho, meta, and para-positioning of 
the respective substituents on the phenyl rings.  
 
 
We previously performed high-throughput screening and discovered 235 small molecule 
inhibitors of the E. coli GroEL/ES chaperonin system.33  We have since found that several of our 
chaperonin inhibitors exhibit antibiotic effects against Gram-positive and Gram-negative bacteria.35  
One of the most potent GroEL/ES inhibitors that we discovered was compound 1 (Figure 3), which 
inhibited both the substrate refolding and ATPase functions of the chaperonin system.33, 35  
Unfortunately, compound 1 was inactive against the panel of bacteria we tested against, suggesting it 
may not be a good candidate for antibacterial development.35  However, we found a related analog in the 
PubChem database where the benzimidazole core is replaced by a benzoxazole (Figure 3, compound 






reported to be active in only 8 bioassays, suggesting this scaffold may be inherently selective and thus a 
promising candidate to explore for further drug development.  Notably, 2e-p was reported as an active 
hit in a high-throughput screen for cytotoxic compounds against Leishmania major promastigotes.  
Because Leishmania are trypanosomatids highly related to Trypanosoma brucei, we postulated that 
compound 1 would also exhibit cytotoxicity to Trypanosoma brucei.    
When we tested compound 1 in a well-established, 72 h cell viability assay employing the T. 
brucei brucei subspecies, we found that it elicited anti-parasitic affects (EC50 7.9 M, Table 1).36, 37  As 
controls for cell viability testing, we included the four primary HAT therapeutics pentamidine (EC50 < 
0.019 M), suramin (EC50 = 0.12 M), nifurtimox (EC50 = 2.8 M), and eflornithine (EC50 > 42 M).  
We note that for safety reasons, in these initial studies we tested hit-to-lead compounds against the T. 
brucei brucei subspecies, which infects animals but not humans, and not the T. brucei gambiense or 
rhodesiense strains that infect humans.  However, we believe that the anti-parasitic effects of HSP60 
inhibitors will likely translate to the human strains since this has been observed with other inhibitor 
classes.38-40  In addition, sequence alignments of the T. brucei brucei and T. brucei gambiense HSP60 
isoforms obtained from the NCBI database indicate the HSP60.1 isoforms are identical between the two 
subspecies (as are HSP10), while the HSP60.2, and HSP60.3 isoforms differ by only two conservative 
amino acid substitutions each (sequences for the T. brucei rhodesiense HSP60 isoforms were not 
available).41  From our previous antibacterial testing, we found that compound 1 exhibited moderate 
cytotoxicity to human liver (THLE-3) and kidney (HEK 293) cell lines in an established cell culture 
assay that measures compound cytotoxicity over a 72 h time course.35  Therefore, in the present study, 
we developed a set of analogs to try to enhance their anti-parasitic effects against T. brucei while 
reducing off-target cytotoxicity to human liver and kidney cells.  We synthesized two series of 
compound 1 analogs through simple coupling of sulfonyl chlorides with the 5-amino-2-(4-
aminophenyl)benzoxazole core (Scheme 1).42, 43  The first series was designed to probe the effects of a 
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variety of substituents and substitution patterns on the sulfonamide end-capping phenyl group (Table 1).  
The second series was designed to probe what alkyl and aryl groups would be tolerated adjacent to the 
sulfonamide linkers (Table 2).   
Scheme 1.  General methods to synthesize inhibitor analogs.42, 43  Coupling of sulfonyl chlorides with 
the 5-amino-2-(4-aminophenyl)benzoxazole core provided the primary bis-sulfonamide inhibitors.  
Three general secondary reactions were employed to further transform substituents: Series 2h – methoxy 
deprotection to hydroxyls; Series 2j – nitro reduction to amines; and Series 2m – ester hydrolysis to 







































Table 1.  Biochemical IC50 and cell viability EC50 results for chaperonin inhibitors based on the 
compound 2 scaffold where R = phenyl with variable ortho, meta, and para-substituents as presented.  
































































































































































































































































































































































T. brucei THLE3 (Liver)
HEK 293 
(Kidney)Refolding ATPase Refolding ATPase
3.9 4.6 >100 >250 6.4 19 15
>100Pentamidine >250 <0.019 19
Nifurtimox >250 2.8 >100
Suramin
>63 >100 >250 >100
Eflornithine
>63 >100 >250 >100 >100
>63 7.9 >250 11 >250 0.12 >100 >100
>63 >100 >250 >100 >250 >42 >100 >100
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Table 2.  Biochemical IC50 and cell viability EC50 results for chaperonin inhibitors where the 




We found that the T. brucei HSP60 chaperonins could not be readily obtained from E. coli 
expression systems as they formed intractable inclusion bodies.  Thus, we used E. coli GroEL/ES as a 
surrogate and tested compounds using our two primary biochemical assays that evaluate for inhibition of 
GroEL/ES-dMDH refolding and ATPase activity over time.35  These assays employed 50 nM of GroEL 
oligomer (700 nM monomeric subunits) and physiological concentrations of ATP (1 mM), and thus low 
























































































































concentrations.  Of the 49 new analogs, 39% are more potent than the initial compound 1 hit (Tables 1 
and 2).  Aryl groups adjacent to the sulfonamide linkers generally provide the most potent GroEL/ES 
inhibitors.  We believe the compounds directly interact with GroEL as they do not inhibit the native 
MDH reporter reaction (Figure 4A).  Furthermore, there is a strong correlation between inhibiting the 
refolding and ATPase functions of the chaperonin system (Figure 4B), suggesting compounds may bind 
to the ATP sites of GroEL.  Consistent with binding to the ATP pockets, series 2h and 2j are the most 
potent inhibitors as their -OH and -NH2 groups putatively hydrogen bond with the catalytic D398 
aspartate, while series 2m inhibitors are the least effective putatively owing to charge-charge repulsion 
of their carboxylates with the D398 aspartate.  Binding in such a mode would also position one of the 
sulfonamide linkers in proximity to mimic a phosphate group of ATP; however, the requirement of the 
sulfonamide linkers for potent inhibition remains to be determined.  While we included the four primary 
HAT therapeutics pentamidine, suramin, nifurtimox, and eflornithine as putative negative controls in our 
biochemical assays, we were surprised to find that suramin actually inhibits the E. coli GroEL/ES 
chaperonin system.  This result could have profound implications on suramin’s mechanism of action 
against T. brucei parasites. 
Figure 4.  A.  Compounds selectively inhibit in the E. coli GroEL/ES-dMDH refolding assay without 
targeting the native MDH reporter reaction.  B.  A strong correlation between IC50 values for the 
GroEL/ES-dMDH refolding and ATPase assays suggests the compounds interact directly with the 
chaperonin system, and are putatively binding to the ATP pockets.  C.  Chaperonin inhibitors are 
cytotoxic to T. brucei parasites.  Correlation plots include data from compounds in both Table 1 (black 
circles) and Table 2 (white circles).  Data plotted in the grey zones represent results beyond the assay 
detection limits (i.e. >100 M for the GroEL/ES-dMDH refolding assay, >63 M for the native MDH 
activity assay, >250 M for the chaperonin-mediated ATPase assay, and >42 M for the T. brucei cell 
viability assay).  Results for suramin (grey square), which is a HAT drug that was found to be a potent 





We next evaluated chaperonin inhibitors for their ability to block the proliferation of T. brucei 
brucei parasites and found that most of the compounds are cytotoxic (Figure 4C).  The scatter in the 
correlation between IC50/EC50 values could indicate that compounds hit another target in addition to the 
HSP60/10 chaperonin systems in parasites.  It could also be that E. coli GroEL/ES is not a suitable 
surrogate to test with in lieu of the three T. brucei HSP60/10 systems.  For instance, compounds may 
exhibit variable structure-activity relationships (SAR) against each of the three T. brucei HSP60 
isoforms, which siRNA knock-down studies suggest would have differing effects on parasite viability.26  
In addition, localization differences between the three T. brucei HSP60 isoforms could significantly 
influence inhibitor effects against each and further complicate cytotoxicity profiles.  We will investigate 
inhibitor mechanisms of action in parasites in future studies. 
Through counter-screening against human mitochondrial HSP60/10, using procedures analogous 
to the GroEL/ES-based assays, we found that inhibitors are highly selective for bacterial GroEL/ES 
(Figure 5A).  However, the high selectivity we observe raises the question of why do these compounds 
not inhibit human HSP60 more potently than they do, considering E. coli GroEL and human HSP60 
share ~95% amino acid identity in their ATP binding sites.  We postulate this could be because these 
inhibitors bind to the trans-ring ATP pockets and allosterically lock up the double-ring GroEL, which 
functions through an obligate, two-stroke mechanism.  This unique mode of inhibition would not be 
possible with human HSP60, which likely functions through a single-ring mechanism.44-46  While we 
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hoped that the lack of inhibition of human mitochondrial HSP60/10 in vitro would translate to low 
cytotoxicity to human cells, we found that many compounds are still moderately toxic to human liver 
(THLE-3) and kidney (HEK 293) cells (Figure 5B).  That many compounds are cytotoxic despite their 
being poor inhibitors of human HSP60/10 may suggest off-target effects in human cells.  We will 
identify potential off-target pathways that these inhibitors could be modulating in future studies.   
 
Figure 5.  A.  Compounds selectively inhibit the refolding cycles of the E. coli GroEL/ES over the 
human HSP60/10 chaperonin system.  B.  Many compounds exhibit moderate cytotoxicity to human 
liver and kidney cell lines, even though they do not inhibit the HSP60/10 refolding cycle in vitro.  C.  
Compounds are generally more cytotoxic to T. brucei parasites over human liver and kidney cells.  Data 
plotted in the grey zones represent results beyond the assay detection limits (i.e. >100 M for the 
chaperonin-mediated dMDH refolding assays, >100 M for the human liver and kidney cell cytotoxicity 
assays, and >42 M for the T. brucei cell viability assay).  Correlation plots include data from both 
Table 1 and 2 compounds.   
 
While a general trend is noted when comparing cytotoxicity of compounds to T. brucei parasites 
with human liver and kidney cells (Figure 5C), we found that inhibitors are usually more selective for 
the parasites.  A few compounds exhibit moderate to high selectivity for parasites over human cells: e.g. 
compounds 2c-o, 2c-p, 2d-p, 2e-o/m/p, 2g-o, 2g-p, 2l-o, and 2l-p, as well as the two naphthyl-containing 
analogs, 10 and 13.  Intriguingly, it appears that substituents extending outwards from the ortho and 
para-positions on the phenyl ring could provide an advantage for selectively targeting T. brucei 
parasites over human liver and kidney cells.  These studies have importantly provided structural leads 
that we can pursue in future optimization studies.  We will investigate how adding a variety of 
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substituents to these and other aryls, as well as altering the sulfonamide linkers and the 2-
phenylbenzoxazole core, will affect inhibitor potency and selectivity in future studies.  We appreciate 
that lead inhibitors are pushing the higher limits of the Lipinski criteria (e.g. compound 10 has a MW of 
606 g/mol and clogP of 7.3); therefore, to develop lead candidates that overcome the pharmacological 
deficiencies of current HAT therapeutics, we will also need to investigate inhibitor oral bioavailability, 
blood-brain barrier permeability, metabolic stability, and pharmacokinetic/pharmacodynamics profiles 
in vitro and in vivo. 
In conclusion, we have developed a new series of chaperonin inhibitors that exhibit antibiotic 
effects against Trypanosoma brucei parasites in cell culture.  While many of these initial analogs exhibit 
moderate cytotoxicity to human liver and kidney cells, the SAR generated from this study has provided 
valuable guidance on molecular substructures to pursue for increasing the therapeutic windows of these 
chaperonin-targeting antibiotic candidates.  We are also exploring additional hits from our previous 
GroEL/ES high-throughput screening to identify alternative scaffolds that selectively kill T. brucei 
parasites.  One of the most significant findings from this study is that the first-line therapeutic for 
African sleeping sickness, suramin, also inhibits both E. coli GroEL/ES and human HSP60/10.  This 
suggests that suramin can inhibit one or all of the three T. brucei HSP60 isoforms in parasites; however, 
this may not be suramin’s primary mechanism of action as it has been found to interact with several 
biological pathways.47-53  Indeed, suramin’s promiscuity against several different targets (i.e. 
polypharmacological effects) may be why this drug has been successful against T. brucei parasites for 
the past 100 years.  It will be intriguing to investigate the contribution that inhibiting the three T. brucei 
HSP60 isoforms makes to the antibiotic efficacy of suramin.  Importantly, these new findings further 
support accumulating evidence that chaperonin-targeting drugs can be developed even though they may 
inhibit human HSP60/10 biochemical functions in vitro.  While we are using T. brucei as the model 
15 
 
parasite to identify the viability of a chaperonin-targeting antibiotic strategy, our studies will open the 
possibility of targeting the chaperonin systems of a wide range of eukaryotic pathogens. 
 
Supporting Information:  Supporting information associated with this article can be found in the 
online version, which includes tabulations of log(IC50) and log(EC50) results with standard deviations; 
experimental protocols for biochemical and cell-based assays; synthetic protocols and 1H-NMR, LC-
MS, and HPLC characterization data for all compounds. 
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Table S1.  Log-transformed values for Table 1 IC50 and EC50 results.  Results are presented as log(IC50 or 
EC50 /M) values ± their standard deviations (SD). 
 
 
-CH3 1e - p >1.8 1.33 ± 0.68 2.12 ± 0.10 1.95 ± 0.08 2.02 ± 0.16 0.90 ± 0.11 1.47 ± 0.23 1.53 ± 0.24
-H 2a >1.8 0.60 ± 0.33 0.66 ± 0.06 >2 >2.4 0.80 ± 0.08 1.28 ± 0.02 1.18 ± 0.13
- o >1.8 1.34 ± 0.27 >2.4 1.88 ± 0.12 >2.4 1.27 ± 0.04 1.74 ± 0.05 1.50 ± 0.03
2b - m >1.8 0.72 ± 0.17 0.71 ± 0.06 1.83 ± 0.13 >2.4 1.00 ± 0.09 1.30 ± 0.04 1.38 ± 0.07
- p >1.8 0.58 ± 0.23 0.63 ± 0.09 >2 >2.4 0.64 ± 0.12 1.27 ± 0.07 1.33 ± 0.11
- o >1.8 1.66 ± 0.18 2.12 ± 0.07 >2 >2.4 0.77 ± 0.05 1.38 ± 0.10 1.87 ± 0.10
2c - m >1.8 1.26 ± 0.43 >2.4 >2 >2.4 0.65 ± 0.13 1.24 ± 0.06 1.33 ± 0.08
- p >1.8 1.36 ± 0.30 1.54 ± 0.17 1.98 ± 0.03 >2.4 0.50 ± 0.14 1.26 ± 0.12 1.12 ± 0.08
- o >1.8 1.80 ± 0.11 2.16 ± 0.05 >2 >2.4 1.44 ± 0.14 1.56 ± 0.03 1.45 ± 0.08
2d - m >1.8 1.37 ± 0.13 1.65 ± 0.07 >2 >2.4 0.90 ± 0.10 1.31 ± 0.09 1.40 ± 0.13
- p >1.8 1.39 ± 0.27 1.28 ± 0.19 >2 >2.4 0.38 ± 0.15 1.20 ± 0.16 1.33 ± 0.18
- o >1.8 >2 2.29 ± 0.11 >2 >2.4 0.25 ± 0.42 1.23 ± 0.17 1.40 ± 0.14
2e - m >1.8 1.54 ± 0.23 >2.4 >2 >2.4 0.69 ± 0.06 1.25 ± 0.11 1.81 ± 0.06
- p >1.8 1.56 ± 0.23 1.66 ± 0.04 >2 >2.4 0.49 ± 0.16 1.02 ± 0.03 1.85 ± 0.17
- o >1.8 1.39 ± 0.23 1.33 ± 0.02 >2 >2.4 1.45 ± 0.16 1.69 ± 0.11 1.82 ± 0.12
2f - m >1.8 1.19 ± 0.08 2.33 ± 0.16 >2 >2.4 0.68 ± 0.11 1.28 ± 0.03 1.18 ± 0.06
- p >1.8 1.54 ± 0.36 >2.4 1.79 ± 0.35 >2.4 0.61 ± 0.10 1.32 ± 0.14 >2
- o >1.8 1.86 ± 0.15 >2.4 >2 >2.4 0.44 ± 0.19 >2 1.90 ± 0.17
2g - m >1.8 1.68 ± 0.07 >2.4 >2 >2.4 0.70 ± 0.09 1.16 ± 0.06 1.44 ± 0.15
- p >1.8 1.55 ± 0.10 1.92 ± 0.01 >2 >2.4 0.51 ± 0.12 >2 1.94 ± 0.16
- o 1.52 ± 0.05 0.88 ± 0.17 1.55 ± 0.16 1.13 ± 0.19 1.52 ± 0.07 0.70 ± 0.08 1.27 ± 0.09 1.27 ± 0.12
2h - m 1.67 ± 0.04 -0.05 ± 0.24 -0.10 ± 0.13 1.28 ± 0.24 1.79 ± 0.07 0.95 ± 0.13 1.57 ± 0.05 1.55 ± 0.04
- p 1.70 ± 0.10 -0.47 ± 0.44 -0.50 ± 0.16 1.06 ± 0.31 1.77 ± 0.09 1.33 ± 0.10 1.62 ± 0.08 1.58 ± 0.06
- o >1.8 0.56 ± 0.23 0.49 ± 0.11 1.88 ± 0.11 2.29 ± 0.10 >1.6 1.97 ± 0.05 1.78 ± 0.05
2i - m >1.8 1.03 ± 0.67 >2.4 1.78 ± 0.03 >2.4 1.02 ± 0.08 1.57 ± 0.06 1.66 ± 0.06
- p >1.8 1.41 ± 0.15 >2.4 1.82 ± 0.24 >2.4 1.19 ± 0.04 1.56 ± 0.05 1.77 ± 0.07
- o >1.8 1.01 ± 0.26 >2.4 >2 >2.4 0.52 ± 0.17 1.25 ± 0.16 1.14 ± 0.14
2j - m >1.8 0.45 ± 0.35 0.98 ± 0.58 1.94 ± 0.10 2.10 ± 0.10 1.18 ± 0.05 1.48 ± 0.02 1.76 ± 0.27
- p >1.8 0.16 ± 0.29 0.22 ± 0.15 1.83 ± 0.15 2.35 ± 0.08 1.34 ± 0.07 1.58 ± 0.20 1.77 ± 0.18
- o >1.8 1.50 ± 0.17 >2.4 1.93 ± 0.08 2.29 ± 0.04 1.37 ± 0.11 1.97 ± 0.04 1.87 ± 0.19
2k - m >1.8 0.88 ± 0.20 0.61 ± 0.03 1.96 ± 0.03 >2.4 1.59 ± 0.12 1.96 ± 0.03 1.65 ± 0.04
- p >1.8 1.56 ± 0.11 >2.4 1.80 ± 0.19 >2.4 1.20 ± 0.13 1.89 ± 0.08 1.66 ± 0.11
- o >1.8 1.55 ± 0.10 1.73 ± 0.10 >2 ± >2.4 1.45 ± 0.25 >2 >2
2l - m >1.8 1.03 ± 0.47 >2.4 1.98 ± 0.04 >2.4 >1.6 1.69 ± 0.22 >2
- p >1.8 1.42 ± 0.11 1.96 ± 0.03 1.94 ± 0.08 >2.4 1.36 ± 0.18 >2 >2
- o >1.8 >2 >2.4 >2 >2.4 >1.6 >2 >2
2m - m 1.62 ± 0.05 1.78 ± 0.13 >2.4 1.91 ± 0.12 >2.4 >1.6 >2 >2
- p >1.8 1.92 ± 0.14 >2.4 >2 ± >2.4 >1.6 >2 >2
>1.8 >2 >2.4 >2 >2.4 <-1.7 1.27 ± 0.11 >2
>1.8 0.90 ± 0.19 >2.4 1.06 ± 0.09 >2.4 -0.92 ± 0.15 >2 >2
>1.8 >2 >2.4 >2 >2.4 0.45 ± 0.09 >2 >2






















T. brucei THLE3 (Liver)
HEK 293 
(Kidney)Refolding ATPase Refolding ATPase
Cell Viability EC 50 Results (M)
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Table S2.  Log-transformed values for Table 2 IC50 and EC50 results.  Results are presented as log(IC50 or 




2a >1.8 0.60 ± 0.33 0.66 ± 0.06 >2 >2.4 0.80 ± 0.08 1.28 ± 0.02 1.18 ± 0.13
3 >1.8 >2 >2.4 >2 >2.4 >1.6 >2 >2
4 >1.8 1.60 ± 0.16 >2.4 1.99 ± 0.04 >2.4 >1.6 >2 >2
5 >1.8 >2 >2.4 >2 >2.4 1.25 ± 0.06 >2 >2
6 >1.8 0.66 ± 0.24 0.83 ± 0.21 1.75 ± 0.17 >2.4 1.24 ± 0.09 1.64 ± 0.03 1.42 ± 0.08
7 >1.8 1.74 ± 0.12 2.32 ± 0.06 >2 >2.4 1.11 ± 0.14 1.46 ± 0.03 1.27 ± 0.05
8 >1.8 1.51 ± 0.19 >2.4 1.82 ± 0.15 2.33 ± 0.09 >1.6 1.76 ± 0.05 1.65 ± 0.01
9 >1.8 1.34 ± 0.50 2.10 ± 0.10 1.99 ± 0.05 2.18 ± 0.09 >1.6 >2 1.72 ± 0.19
10 >1.8  1.36 ± 0.64 1.73 ± 0.14  >2 2.16 ± 0.11  0.32 ± 0.06  1.84 ± 0.28 >2
11 >1.8 0.57 ± 0.55 0.22 ± 0.08 1.80 ± 0.31 2.10 ± 0.06 >1.6 1.65 ± 0.18 1.88 ± 0.12
12 >1.8 -0.09 ± 0.55 -0.26 ± 0.09 1.69 ± 0.31 >2.4 1.40 ± 0.11 1.48 ± 0.01 1.98 ± 0.09
13 >1.8 1.61 ± 0.17 1.82 ± 0.15 >2 2.10 ± 0.11 0.57 ± 0.17 1.74 ± 0.29 >2
14 >1.8 1.25 ± 0.11 1.92 ± 0.18 1.84 ± 0.15 2.30 ± 0.13 >1.6 >2 >2
Compound & 
Substructures Refolding ATPase










General Materials and Methods.   
DH5α and BL21 (DE3) E. coli cells were purchased from New England Biolabs, and Rosetta™ 2 (DE3) 
E. coli cells from EMD Millipore.  Trypanosoma brucei brucei Plimmer and Bradford parasites (Lister 427 
VSG 221 [TetR T7RNAP] transgenic bloodstream form) were obtained from the ATCC (PRA-383).  HEK 293 
kidney and THLE-3 liver cells were obtained from the ATCC (CRL-1573 and CRL-11233, respectively).  
Antibiotics were used in following concentrations when appropriate; Kanamycin (34 μg/mL), ampicillin (50 
μg/mL), chloramphenicol (30 μg/mL) and streptomycin (100 μg/mL).  Unless otherwise stated, all chemicals 
were purchased from commercial suppliers and used without further purification.  All test compounds were 
synthesized according to literature procedures for similar molecules.1, 2  Reaction progress was monitored by 
thin-layer chromatography on silica gel 60 F254 coated glass plates (EM Sciences).  Flash chromatography was 
performed using a Biotage Isolera One flash chromatography system and eluting through Biotage KP-Sil Zip or 
Snap silica gel columns for normal phase separations (hexanes:EtOAc gradients) or Snap KP-C18-HS columns 
for reverse phase separations (H2O:MeOH gradients).  Reverse phase high performance liquid chromatography 
(RP-HPLC) was performed using a Waters 1525 binary pump, 2489 tunable UV/Vis detector (254 and 280 nm 
detection), and 2707 autosampler.  For preparatory HPLC purification, samples were chromatographically 
separated using a Waters XSelect CSH C18 OBD prep column (part number 186005422, 130 Å pore size, 5 m 
particle size, 19x150 mm), eluting with a H2O:CH3CN gradient solvent system.  Linear gradients were run from 
either 100:0, 80:20, or 60:40 A:B to 0:100 A:B (A = 95:5 H2O:CH3CN, 0.05% TFA; B = 5:95 H2O:CH3CN, 
0.05% TFA.  For primary purity analyses (HPLC-1), samples were chromatographically separated using a 
Waters XSelect CSH C18 column (part number 186005282, 130 Å pore size, 5 m particle size, 3.0x150 mm), 
eluting with the above H2O:CH3CN gradient solvent systems.  For secondary purity analyses (HPLC-2), 
samples were chromatographically separated using a Waters XBridge C18 column (part number 186003027, 
130 Å pore size, 3.5 m particle size, 3.0x100 mm), eluting with a H2O:MeOH gradient solvent system.  Linear 
gradients were run from either 100:0, 80:20, 60:40, or 20:80 A:B to 0:100 A:B (A = 95:5 H2O:MeOH, 0.05% 
TFA; B = 5:95 H2O:MeOH, 0.05% TFA).  Test compounds were found to be >95% in purity from both RP-
HPLC analyses.  Mass spectrometry data were collected using an Agilent analytical LC-MS at the IU Chemical 
Genomics Core Facility (CGCF).  1H-NMR spectra were recorded on either a Bruker 300 MHz or Bruker 500 
MHz spectrometer.  Chemical shifts are reported in parts per million and calibrated to the d6-DMSO solvent 
peaks at 2.50 ppm. 
 
Protein Expression and purification.   
E. coli GroEL and GroES, and human mitochondrial HSP60 and HSP10 were expressed and purified as 
previously reported.3  Protein concentrations were determined using a Coomassie Protein Assay Kit (Thermo 
Scientific).  Proteins were stored at 4°C in 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, and 1 mM DTT.  E. coli 
GroEL and GroES proteins were discarded after 30 days, and human HSP60 and HSP10 were discarded after 10 
days. 
 
Calculation of IC50 and EC50 values. 
All IC50 (or EC50) values reported are averages of IC50 (or EC50) values determined from individual 
dose-response curves in replicate assays as follows: 1) Individual IC50 values from replicate assays were first 
log-transformed and the average log(I/EC50) values and standard deviations (SD) calculated; 2) Replicate 
log(I/EC50) values were evaluated for outliers using the ROUT method in GraphPad Prism 6 (Q of 10%); and   
3) Average IC50 (or EC50) values were then back-calculated from the average log(I/EC50) values.   
 
GroEL/ES and HSP60/10-mediated dMDH refolding assay protocols. 
The GroEL/ES-dMDH and HSP60/10-dMDH refolding assays were conducted as previously reported,3 
with one minor procedural difference: instead of quenching the refolding reactions with EDTA at the 60 minute 
time point, the refolding reactions were quenched when they reached ~90% completion (as determined from 
refolding time-course control experiments – generally ~20-40 min for GroEL/ES, and ~40-60 min for 
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HSP60/10).  Compounds were tested in 8-point, 3-fold dilution series (100 M to 46 nM) in clear, flat-bottom 
384-well microtiter plates.  DMSO was used as negative control, and previously discovered chaperonin 
inhibitors were used as positive controls.3, 4  IC50 values for the test compounds were obtained by plotting the % 
inhibition results in GraphPad Prism 6 and analyzing by non-linear regression using the log (inhibitor) vs. 
response (variable slope) equation.  Results presented represent the averages of IC50 values obtained from at 
least triplicate experiments.  
 
Native MDH enzymatic activity counter-screen assay protocol. 
This assay was performed as described above for the GroEL/ES-dMDH refolding assay, but the 
compounds were pin-transferred after the EDTA quench step. Thus, only the enzymatic portion of the assay was 
in the presence of test compounds to identify their effects on the native MDH reporter substrate.  Compounds 
were tested in 8-point, 3-fold dilution series (62.5 M to 29 nM) in clear, flat-bottom 384-well microtiter plates.  
DMSO was used as negative control, and previously discovered native MDH inhibitors were used as positive 
controls.3, 4  IC50 values for the test compounds were obtained by plotting the % inhibition results in GraphPad 
Prism 6 and analyzing by non-linear regression using the log (inhibitor) vs. response (variable slope) equation.  
Results presented represent the averages of IC50 values obtained from at least triplicate experiments. 
 
Chaperonin-dependent ATPase activity assay protocol. 
The GroEL/ES-dMDH and HSP60/10-dMDH ATPase assays were conducted as previously reported,3 
with the procedural differences as noted above that the refolding reactions were quenched when they reached 
~90% completion (as determined from refolding time-course control experiments – generally ~20-40 min for 
GroEL/ES, and ~40-60 min for HSP60/10).  Compounds were tested in 8-point, 3-fold dilution series (250 M 
to 114 nM) in clear, flat-bottom 384-well microtiter plates.  DMSO was used as negative control, and 
previously discovered chaperonin inhibitors were used as positive controls.3, 4  A second set of baseline control 
plates were prepared analogously, but without binary solution, to correct for possible interference from 
compound absorbance or turbidity.  IC50 values for the test compounds were obtained by plotting the OD600 
results in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response 
(variable slope) equation.  Results presented represent the averages of IC50 values obtained from at least 
triplicate experiments. 
 
T. brucei cell viability assay protocol. 
Test compounds were evaluated using a robust T. brucei cell viability assay in 384-well plate format as 
previously reported.5, 6  Briefly, 55 μL of 2000 parasites/mL (110 parasites/well) of Trypanosoma brucei brucei 
(strain BF427) in HMI-9 medium were dispensed in to clear, 384-well polystyrene plates (BRAND cell culture 
grade plates, 781980).  Plates were sealed with "Breathe Easy" oxygen permeable membranes (Diversified 
Biotech) and incubated at 37°C, 5% CO2 for 24 h.  Next, 1 µL of the compound stocks (10 mM to 4.6 µM, 3-
fold dilutions in DMSO) were pre-diluted by pin-transfer into 20 µL HMI-9 medium, then 5 µL of these diluted 
compounds were added to the parasite assay plates to give an inhibitor concentration range of 42 µM to 19 nM 
during the assay (the final DMSO concentration of 0.42% was maintained during the assay).  Parasites were 
incubated for an additional 48 h at 37°C and 5% CO2.  Cell viability was then measured by adding 10 µL of 
Alamar Blue reagent to give 10% v/v in the assay.  Plates were incubated for 3 h at 37°C and 5% CO2, then for 
another 22 h in dark at room temperature.  Sample fluorescence (535 nm excitation, 590 nm emission) was read 
using a Molecular Devices FlexStation II 384-well plate reader, and cell viability was calculated as per vendor 
instructions.  EC50 values for the test compounds were obtained by plotting the % Alamar Blue reduction results 
in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response (variable 
slope) equation.  DMSO was used as negative control, and pentamidine, suramin, and nifurtimox (drugs used to 
treat HAT) were used as positive controls.  Results presented represent the averages of EC50 values obtained 
from at least triplicate experiments 
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HEK 293 and THLE-3 cytotoxicity assay protocol.   
Cell cytotoxicity assays were performed using the Alamar Blue reporter reagents as previously 
described.3, 5, 6  Compounds were tested in 8-point, 3-fold dilution series (100 M to 46 nM) in 384-well plates 
(BRAND cell culture grade plates, 781980).  DMSO was used as negative control, and previously discovered 
cytotoxic chaperonin inhibitors were used as positive controls.3, 4  Sample fluorescence (535 nm excitation, 590 
nm emission) was read using a Molecular Devices FlexStation II 384-well plate reader, and cell viability was 
calculated as per vendor instructions.  EC50 values for the test compounds were obtained by plotting the % 
Alamar Blue reduction results in GraphPad Prism 6 and analyzing by non-linear regression using the 
log(inhibitor) vs. response (variable slope) equation.  Results presented represent the averages of EC50 values 
obtained from at least triplicate experiments. 
 
General Synthetic Methods. 
 
Synthetic Protocol A: General procedure for the synthesis of bis-sulfonamide analogues. 
 To a stirring mixture of 5-amino-2-(4-aminophenyl) benzoxazole (1 eq.) in anhydrous CH2Cl2 (5 mL) 
was added the respective sulfonyl chloride (2.1 eq.) followed by anhydrous pyridine (2.1 eq.).  The reaction was 
allowed to stir at room temperature for 18 h and was then chromatographed over silica and concentrated.  If 
necessary, the product was further purified by preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and 
lyophilized.  Refer below for individual compound synthesis and characterization data. 
.................................................................................................................................................................................... 
 
 Synthetic Protocol B: General procedure for methoxy-to-hydroxy deprotections. 
 To a stirring mixture of the respective bis-sulfonamide (1 eq.) or mono-sulfonamide (1 eq.) in anhydrous 
CH2Cl2 (5 mL), was added BBr3 (6 eq. or 3 eq., respectively, in CH2Cl2). The reaction was allowed to stir at 
room temperature for 18 h and then diluted drop-wise with MeOH (2 mL). The reaction was then washed with 
brine and extracted into EtOAc. The organics were dried over Na2SO4, filtered, and concentrated. The crude 
product was chromatographed over silica and concentrated.  If necessary, the product was further purified by 
preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and lyophilized.  Refer below for individual 
compound synthesis and characterization data. 
.................................................................................................................................................................................... 
 
Synthetic Protocol C: General procedure for nitro-to-amine reductions. 
 To the respective bis-sulfonamide (1 eq.) or mono-sulfonamide (1 eq.) was added tin powder (6 eq. or 3 
eq., respectively), followed by a 1:10 mixture of HCl:AcOH (generally 0.2:2.0 mL). The reaction was allowed 
to stir at room temperature for 18 h, then diluted with EtOAc and H2O, neutralized with NaHCO3, and filtered. 
The filtrate was extracted with EtOAc and the organics dried over Na2SO4, filtered, and concentrated. The crude 
product was then chromatographed over silica and concentrated.  If necessary, the product was further purified 
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by preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and lyophilized.  Refer below for individual 
compound synthesis and characterization data. 
.................................................................................................................................................................................... 
 
Synthetic Protocol D: General procedure for ester-to-acid hydrolyses. 
 To a stirring mixture of the respective methyl ester compound (1 eq.) in THF (1.5 mL), MeOH (0.5 mL), 
and H2O (0.5 mL), was added LiOH•H2O (~6-10 eq.). The reaction was allowed to stir at room temperature for 
18 h and then was diluted with H20 (10 mL) and acidified with 1M HCl. The precipitate was filtered, washed 
with H2O, and dried. If necessary, the product was further purified by preparatory RP-HPLC (H2O:CH3CN 
gradient), concentrated, and lyophilized.  Refer below for individual compound synthesis and characterization 
data.  
.................................................................................................................................................................................... 
Synthesis of specific test molecules.   
 
2b-o: 2-fluoro-N-(4-(5-((2-fluorophenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (47.0 mg, 0.209 mmol), 2-fluorobenzenesulfonyl 
chloride (69.0 µL, 0.52 mmol), and anhydrous pyridine (42.5 µL, 0.52 mmol) according to synthetic protocol A.  
Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2b-o as a white solid (50.5 mg, 45% 
yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.21 (br s, 1H), 10.66 (br s, 1H), 7.97 (d, J = 8.5 Hz, 2H), 7.92 (t, J = 
6.9 Hz, 1H), 7.76-7.84 (m, 1H), 7.63-7.70 (m, 2H), 7.60 (d, J = 8.8 Hz, 1H), 7.35-7.44 (m, 4H), 7.32 (td, J = 
7.6, 1.1 Hz, 1H), 7.26 (d, J = 8.2 Hz, 2H), 7.10 (dd, J = 8.7, 2.0 Hz, 1H); MS (ESI) 539.8 m/z [M-H+]-, 




was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (59.8 mg, 0.265 mmol), 3-fluorobenzenesulfonyl 
chloride (89.0 µL, 0.663 mmol), and anhydrous pyridine (54.0 µL, 0.662 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2b-m as a white solid (131 mg, 91% 
yield). 1H-NMR (300 MHz, d6-DMSO) δ 10.99 (br s, 1H), 10.47 (br s, 1H), 8.03 (d, J = 8.8 Hz, 2H), 7.40-7.77 
(m, 10H), 7.31 (d, J = 8.8 Hz, 2H), 7.08 (dd, J = 8.7, 2.1 Hz, 1H); MS (ESI) 542.0 m/z [MH+], C25H18F2N3O5S2 





2b-p: 4-fluoro-N-(4-(5-((4-fluorophenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (55.3 mg, 0.246 mmol), 4-fluorobenzenesulfonyl 
chloride (124 mg, 0.637 mmol), and anhydrous pyridine (50.0 µL, 0.613 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2b-p as a white solid (108 mg, 81% 
yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.93 (br s, 1H), 10.35 (br s, 1H), 8.00 (d, J = 8.8 Hz, 2H), 7.83-7.92 
(m, 2H), 7.75-7.80 (m, 2H), 7.61 (d, J = 8.8 Hz, 1H), 7.33-7.43 (m, 5H), 7.27 (d, J = 8.8 Hz, 2H), 7.06 (dd, J = 




was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (59.7 mg, 0.265 mmol), 2-
chlorobenzenesulfonyl chloride (90.0 µL, 0.660 mmol), and anhydrous pyridine (54.0 µL, 0.662 mmol) 
according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2c-o 
as a white solid (74.3 mg, 49% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.21 (s, 1H), 10.67 (s, 1H), 8.11-8.15 
(m, 1H), 8.02 (dd, J = 7.7, 1.4 Hz, 1H), 7.97 (d, J = 8.8 Hz, 2H), 7.53-7.65 (m, 6H), 7.46-7.50 (m, 1H), 7.39 (d, 
J = 2.2 Hz, 1H), 7.26 (d, J = 8.5 Hz, 2H), 7.11 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 571.8 m/z [M-H+]-, 




was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (55.6 mg, 0.247 mmol), 3-
chlorobenzenesulfonyl chloride (87.0 µL, 0.618 mmol), and anhydrous pyridine (50.0 µL, 0.613 mmol) 
according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2c-m 
as a white solid (94.0 mg, 66% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.98 (br s, 1H), 10.45 (br s, 1H), 8.03 
(d, J = 8.8 Hz, 2H), 7.83 (t, J = 1.9 Hz, 1H), 7.53-7.80 (m, 8H), 7.41 (d, J = 2.2 Hz, 1H), 7.31 (d, J = 8.8 Hz, 
2H), 7.07 (dd, J = 8.5, 2.2 Hz, 1H); MS (ESI) 571.7 m/z [M-H+]-, C25H16Cl2N3O5S2 requires 572.0; HPLC-1 = 






was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (62.7 mg, 0.278 mmol), 4-
chlorobenzenesulfonyl chloride (146 mg, 0.693 mmol), and anhydrous pyridine (57.0 µL, 0.699 mmol) 
according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2c-p 
as a white solid (133 mg, 83% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.95 (br s, 1H), 10.42 (br s, 1H), 8.00-
8.04 (m, 2H), 7.81-7.85 (m, 2H), 7.70-7.74 (m, 2H), 7.59-7.67 (m, 5H), 7.40 (d, J = 1.9 Hz, 1H), 7.27-7.32 (m, 
2H), 7.07 (dd, J = 8.7, 2.0 Hz, 1H); MS (ESI) 571.8 m/z [M-H+]-, C25H16Cl2N3O5S2 requires 572.0; HPLC-1 = 




was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (49.0 mg, 0.218 mmol), 2-
bromobenzenesulfonyl chloride (78.5 µL, 0.544 mmol), and anhydrous pyridine (44.0 µL, 0.543 mmol) 
according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2d-o 
as a pink-white solid (84.1 mg, 46% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.22 (s, 1H), 10.60 (s, 1H), 8.16 
(dd, J = 7.9, 1.6 Hz, 1H), 8.07 (dd, J = 7.6, 1.9 Hz, 1H), 7.98 (d, J = 8.5 Hz, 2H), 7.82 (td, J = 8.0, 1.1 Hz, 2H), 
7.57-7.63 (m, 2H), 7.54 (td, J = 7.7, 1.3 Hz, 2H), 7.47-7.51 (m, 1H), 7.28 (d, J = 2.2 Hz, 1H), 7.26 (d, J = 8.5 
Hz, 2H), 7.12 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 659.7 m/z [M-H+]-, C25H16Br2N3O5S2 requires 659.9; HPLC-1 




was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (49.0 mg, 0.218 mmol), 3-
bromobenzenesulfonyl chloride (78.5 µL, 0.544 mmol), and anhydrous pyridine (44.5 µL, 0.543 mmol) 
according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2d-
m as a white solid (41.7 mg, 29% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.97 (br s, 1H), 10.43 (br s, 1H), 
8.03 (d, J = 8.8 Hz, 2H), 7.98 (s, 1H), 7.88 (t, J = 1.7 Hz, 1H), 7.80-7.86 (m, 3H), 7.69 (dq, J = 7.9, 0.8 Hz, 1H), 
7.64 (d, J = 8.5 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.40 (d, J = 1.9 Hz, 1H), 7.30 (d, J = 
7.9 Hz, 2H), 7.07 (dd, J = 8.7, 2.0 Hz, 1H); MS (ESI) 659.7 m/z [M-H+]-, C25H16Br2N3O5S2 requires 659.9; 
















was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (53.6 mg, 0.238 mmol), 4-
bromobenzenesulfonyl chloride (155 mg, 0.606 mmol), and anhydrous pyridine (48.5 µL, 0.595 mmol) 
according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2d-p 
as a white solid (38.6 mg, 24% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.95 (br s, 1H), 10.42 (br s, 1H), 8.02 
(d, J = 8.8 Hz, 2H), 7.77-7.82 (m, 2H), 7.73-7.77 (m, 4H), 7.61-7.65 (m, 3H), 7.40 (d, J = 1.9 Hz, 1H), 7.29 (d, 
J = 8.8 Hz, 2H), 7.06 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 661.8 m/z [MH+], C25H18Br2N3O5S2 requires 661.9; 




was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (51.9 mg, 0.230 mmol), o-toluenesulfonyl 
chloride (83.0 µL, 0.575 mmol), and anhydrous pyridine (47.0 µL, 0.576 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2e-o as a white solid (64.5 mg, 53% 
yield). 1H-NMR (300 MHz, d6-DMSO) δ 11.03 (s, 1H), 10.47 (s, 1H), 7.94-8.00 (m, 3H), 7.86 (d, J = 7.6 Hz, 
1H), 7.58 (d, J = 8.8 Hz, 1H), 7.30-7.55 (m, 7H), 7.24 (d, J = 8.8 Hz, 2H), 7.06 (dd, J = 8.8, 2.1 Hz, 1H), 2.60 





was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (52.8 mg, 0.234 mmol), m-toluenesulfonyl 
chloride (85.0 µL, 0.586 mmol), and anhydrous pyridine (48.0 µL, 0.589 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2e-m as a white solid (101 mg, 81% 
yield). 1H-NMR (300 MHz, d6-DMSO) δ 10.86 (br s, 1H), 10.32 (br s, 1H), 8.00 (d, J = 8.8 Hz, 2H), 7.38-7.69 
(m, 10H), 7.30 (d, J = 8.8 Hz, 2H), 7.07 (dd, J = 8.7, 2.1 Hz, 1H), 2.34 (s, 3H), 2.31 (s, 3H); MS (ESI) 534.0 






was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (45.9 mg, 0.204 mmol), p-toluenesulfonyl 
chloride (85.1 mg, 0.466 mmol), and anhydrous pyridine (35.0 µL, 0.429 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2e-p as a yellow solid (29.5 mg, 
27% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.82 (br s, 1H), 10.26 (br s, 1H), 7.76-8.02 (m, 2H), 7.70-7.75 
(m, 2H), 7.57-7.63 (m, 3H), 7.34-7.39 (m, 3H), 7.26-7.34 (m, 4H), 7.07 (dd, J = 8.5, 2.2 Hz, 1H), 2.32 (s, 3H), 




yl)phenyl)benzenesulfonamide was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (45.4 mg,0.202 
mmol), 2-trifluoromethyl-benzenesulfonyl chloride (117 µL, 0.785 mmol), and anhydrous pyridine (54.0 µL, 
0.662 mmol) according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2f-o as a white solid (124 mg, 96% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.24 (br s, 1H), 10.73 
(br s, 1H), 8.13-8.17 (m, 1H), 8.10 (d, J = 7.6 Hz, 1H), 8.00-8.05 (m, 3H), 7.98 (dd, J = 7.4, 1.4 Hz, 1H), 7.78-
7.90 (m, 4H), 7.64 (d, J = 8.8 Hz, 1H), 7.41 (d, J = 1.9 Hz, 1H), 7.29 (d, J = 8.8 Hz, 2H), 7.12 (dd, J = 8.8, 2.2 




yl)phenyl)benzenesulfonamide was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (48.5 mg, 0.215 
mmol), 3-trifluoromethylbenzenesulfonyl chloride (86.0 µL, 0.536 mmol), and anhydrous pyridine (39.0 µL, 
0.478 mmol) according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2f-m as a white solid (74.0 mg, 54% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.01 (br s, 1H), 10.48 
(br s, 1H), 8.05-8.13 (m, 2H), 7.95-8.05 (m, 6H), 7.83 (t, J = 7.9 Hz, 1H), 7.77 (t, J = 7.9 Hz, 1H), 7.64 (d, J = 
8.8 Hz, 1H), 7.40 (d, J = 1.9 Hz, 1H), 7.31 (d, J = 8.8 Hz, 2H), 7.06 (dd, J = 8.7, 2.0 Hz, 1H); MS (ESI) 639.9 






yl)phenyl)benzenesulfonamide was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (52.7 mg, 0.234 
mmol), 4-trifluoromethylbenzenesulfonyl chloride (144 mg, 0.589 mmol), and anhydrous pyridine (47.5 µL, 
0.582 mmol) according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2f-p as a yellow solid (56.6 mg, 38% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.09 (br s, 1H), 10.60 
(br s, 1H), 8.03 (dd, J = 8.5, 6.0 Hz, 4H), 7.97 (d, J = 8.5 Hz, 2H), 7.93 (s, 4H), 7.63 (d, J = 8.8 Hz, 1H), 7.43 
(d, J = 2.2 Hz, 1H), 7.31 (d, J = 8.8 Hz, 2H), 7.07 (dd, J = 8.7, 2.0 Hz, 1H); MS (ESI) 641.9 m/z [MH+], 




yl)phenyl)benzenesulfonamide was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (50.5 mg, 0.224 
mmol), 2-methoxybenzenesulfonyl chloride (113 mg, 0.548 mmol), and anhydrous pyridine (45.5 µL, 0.558 
mmol) according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2g-o as a white solid (66.5 mg, 52% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.61 (br s, 1H), 10.04 
(s, 1H), 7.92-7.96 (m, 2H), 7.85 (dd, J = 7.7, 1.7 Hz, 1H), 7.73 (dd, J = 7.7, 1.7 Hz, 1H), 7.50-7.58 (m, 3H), 
7.36 (d, J = 1.9 Hz, 1H), 7.23-7.27 (m, 2H), 7.15 (dd, J = 7.9, 4.4 Hz, 2H), 7.10 (dd, J = 8.8, 2.2 Hz, 1H), 7.04-
7.07 (m, 1H), 6.96-7.00 (m, 1H) 3.89 (s, 3H), 3.84 (s, 3H); MS (ESI) 566.1 m/z [MH+], C27H24N3O7S2 requires 




yl)phenyl)benzenesulfonamide was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (56.3 mg, 0.250 
mmol), 3-methoxybenzenesulfonyl chloride (89.0 µL, 0.629 mmol), and anhydrous pyridine (51.0 µL, 0.625 
mmol) according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2g-m as a white solid (126 mg, 89% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.84 (br s, 1H), 10.32 
(s, 1H), 7.99-8.04 (m, 2H), 7.61 (d, J = 8.8 Hz, 1H), 7.45-7.50 (m, 1H), 7.37-7.44 (m, 3H), 7.26-7.33 (m, 4H), 
7.23-7.25 (m, 1H), 7.19 (ddd, J = 8.3, 2.6, 0.8 Hz, 1H), 7.13-7.16 (m, 1H), 7.09 (dd, J = 8.8, 2.2 Hz, 1H), 3.77 







yl)phenyl)benzenesulfonamide was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (57.5 mg, 0.255 
mmol), 4-methoxybenzenesulfonyl chloride (130 mg, 0.630 mmol), and anhydrous pyridine (48.0 µL, 0.589 
mmol) according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2g-p as a white solid (112 mg, 78% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.73 (br s, 1H), 10.20 
(s, 1H), 7.97-8.02 (m, 2H), 7.75-7.80 (m, 2H), 7.64-7.68 (m, 2H), 7.60 (d, J = 8.8 Hz, 1H), 7.38 (d, J = 2.2 Hz, 
1H), 7.26-7.31 (m, 2H), 7.05-7.10 (m, 3H), 7.00-7.05 (m, 2H), 3.78 (s, 3H), 3.76 (s, 3H); MS (ESI) 566.1 m/z 




yl)phenyl)benzenesulfonamide was synthesized from 2g-o (189 mg, 0.335 mmol) and boron tribromide (2.00 
mL, 2.00 mmol) according to synthetic protocol B.  Flash chromatographic purification (hexanes:EtOAc 
gradient) afforded 2h-o as a tan solid (96.0 mg, 53% yield). 1H-NMR (300 MHz, d6-DMSO) δ 10.91 (br s, 2H), 
10.70 (br s, 1H), 9.99 (br s, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.78 (dd, J = 8.1, 1.6 Hz, 1H), 7.65 (dd, J = 7.9, 1.5 
Hz, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.31-7.44 (m, 3H), 7.26 (d, J = 8.8 Hz, 2H), 7.13 (dd, J = 8.8, 2.0 Hz, 1H), 
6.87-6.96 (m, 3H), 6.79-6.86 (m, 1H); MS (ESI) 538.0 m/z [MH+], C25H20N3O7S2 requires 538.1; HPLC-1 = 




yl)phenyl)benzenesulfonamide was synthesized from 2g-m (78.1 mg, 0.138 mmol) and boron tribromide (0.83 
mL, 0.83 mmol) according to synthetic protocol B.  Flash chromatographic purification (hexanes:EtOAc 
gradient) afforded 2h-m as a yellow solid (31.8 mg, 43% yield). 1H-NMR (300 MHz, d6-DMSO) δ 10.84 (s, 
1H), 10.30 (s, 1H), 10.19 (br s, 1H), 10.09 (br s, 1H), 8.02 (d, J = 88 Hz, 2H), 7.62 (d, J = 8.8 Hz, 1H), 7.23-
7.42 (m, 6H), 7.04-7.21 (m, 4H), 6.90-7.01 (m, 2H); MS (ESI) 538.0 m/z [MH+], C25H20N3O7S2 requires 538.1; 






yl)phenyl)benzenesulfonamide was synthesized from 2g-p (74.5 mg, 0.132 mmol) and boron tribromide (0.80 
mL, 0.80 mmol) according to synthetic protocol B.  Flash chromatographic purification (hexanes:EtOAc 
gradient) afforded 2h-p as a white solid (45.2 mg, 64% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.41 (br s, 
2H), 10.07 (br s, 1H), 7.96 (d, J = 8.2Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H), 7.53-7.60 (m, 3H), 7.35 (d, J = 1.9 Hz, 
1H), 7.22 (d, J = 8.2 Hz, 2H), 7.04 (dd, J = 8.7, 2.0 Hz, 1H), 6.79-6.86 (m, 4H); MS (ESI) 535.8 m/z [M-H+]-, 
C25H18N3O7S2 requires 536.1; HPLC-1 = 95%; HPLC-2 = 95%. 
.................................................................................................................................................................................... 
 
2i-o: 2-nitro-N-(4-(5-((2-nitrophenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (53.6 mg, 0.238 mmol), 2-nitrobenzenesulfonyl 
chloride (185 µL, 0.839 mmol), and anhydrous pyridine (61.0 µL, 0.748 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient), followed by preparatory RP-HPLC 
purification, afforded 2i-o as a yellow solid (143 mg, 101% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.28 (br 
s, 1H), 10.78 (br s, 1H), 8.03-8.07 (m, 3H), 7.99 (d, J = 7.6 Hz, 1H), 7.96 (td, J = 7.5, 1.4 Hz, 2H), 7.77-7.87 
(m, 4H), 7.67 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 2.2 Hz, 1H), 7.31 (d, J = 8.5 Hz, 2H), 7.13 (dd, J = 8.8, 2.2 Hz, 
1H); MS (ESI) 593.8 m/z [M-H+]-, C25H16N5O9S2 requires 594.0; HPLC-1 = 98%; HPLC-2 = 99%. 
.................................................................................................................................................................................... 
 
2i-m: 3-nitro-N-(4-(5-((3-nitrophenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (53.9 mg, 0.239 mmol), 3-nitrobenzenesulfonyl 
chloride (132 µL, 0.593 mmol), and anhydrous pyridine (45.0 µL, 0.552 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient), followed by preparatory RP-HPLC 
purification, afforded 2i-m as a yellow-orange solid (42.9 mg, 30% yield). 1H-NMR (500 MHz, d6-DMSO) δ 
11.11 (br s, 1H), 10.63 (br s, 1H), 8.54 (t, J = 1.9 Hz, 1H), 8.49 (t, J = 1.9 Hz, 1H), 8.40-8.45 (m, 2H), 8.21 (dq, 
J = 7.9, 0.8 Hz, 1H), 8.07 (dq, J = 7.9, 0.8 Hz, 1H), 8.00 (d, J = 8.5 Hz, 2H), 7.77-7.87 (m, 2H), 7.63 (d, J = 8.5 
Hz, 1H), 7.42 (d, J = 2.2 Hz, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.08 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 596.1 m/z 





2i-p: 4-nitro-N-(4-(5-((4-nitrophenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (112 mg, 0.497 mmol), 4-nitrobenzenesulfonyl 
chloride (566 mg, 0.486 mmol), and anhydrous pyridine (100 µL, 0.486 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2i-p as a yellow solid (91.0 mg, 23% 
yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.16 (br s, 1H), 10.67 (br s, 1H), 8.36-8.40 (m, 2H), 8.32-8.36 (m, 
2H), 8.06-8.10 (m, 2H), 8.01-8.05 (m, 2H), 7.94-7.98 (m, 2H), 7.64 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 1.9 Hz, 
1H), 7.30-7.34 (m, 2H), 7.08 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 593.9 m/z [M-H+], C25H16N5O9S2 requires 
594.0; HPLC-1 = 99%; HPLC-2 = >99%. 
.................................................................................................................................................................................... 
 
2j-o: 2-amino-N-(4-(5-((2-aminophenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was 
synthesized from 2i-o (51.9 mg, 0.0871 mmol) and tin powder (62.1 mg, 0.523 mmol) according to synthetic 
protocol C.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2j-o as a white solid (35.7 
mg, 77% yield). 1H-NMR (300 MHz, d6-DMSO) δ 10.80 (br s, 1H), 10.29 (br s, 1H), 7.98 (d, J = 8.8 Hz, 2H), 
7.55-7.64 (m, 2H), 7.43-7.48 (m, 1H), 7.32-7.36 (m, 1H), 7.15-7.25 (m, 4H), 7.04 (dd, J = 8.7, 2.1 Hz, 1H), 
6.70-6.78 (m, 2H), 6.48-6.60 (m, 2H), 6.00 (br s, 4H); MS (ESI) 536.0 m/z [MH+], C25H22N5O5S2 requires 




was synthesized using a different reduction procedure, with addition of NaBH4 (62.3 mg, 1.65 mmol), to a 
stirring mixture of 2i-m (135 mg, 0.227 mmol) and NiSO4 hexahydrate (11.9 mg, 0.045 mmol).  After 15 
minutes, the reaction was diluted with 1 M HCl and the precipitate was filtered, rinsed with water, and 
collected.  Preparatory RP-HPLC purification afforded 2j-m as a white solid (29.0 mg, 24% yield). 1H-NMR 
(300 MHz, d6-DMSO) δ 10.76 (s, 1H), 10.23 (s, 1H), 7.97-8.04 (m, 2H), 7.57-7.64 (m, 1H), 7.39 (d, J = 2.0 Hz, 
1H), 7.25-7.32 (m, 2H), 7.12-7.22 (m, 2H), 7.04-7.10 (m, 2H), 6.88-7.00 (m, 3H), 6.72-7.79 (m, 2H); MS (ESI) 





2j-p: 4-amino-N-(4-(5-((4-aminophenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was 
synthesized from 2i-p (72.4 mg, 0.122 mmol) and tin powder (126 mg, 1.06 mmol) according to synthetic 
protocol C.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2j-p as a pink solid (32.3 
mg, 49% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.50 (br s, 1H), 9.88 (s, 1H), 7.97 (d, J = 8.5 Hz, 2H), 7.56 
(d, J = 8.8 Hz, 1H), 7.46 (d, J = 8.8 Hz, 2H), 7.34-7.37 (m, 3H), 7.23 (d, J = 8.5 Hz, 2H), 7.04 (dd, J = 8.7, 2.0 
Hz, 1H), 6.54 (d, J = 8.8 Hz, 2H), 6.50 (d, J = 8.8 Hz, 2H), 6.00 (br s, 2H), 5.95 (br s, 2H); MS (ESI) 536.0 m/z 
[MH+], C25H22N5O5S2 requires 536.1; HPLC-1 = 98%; HPLC-2 = 97%. 
.................................................................................................................................................................................... 
 
2k-o: 2-cyano-N-(4-(5-((2-cyanophenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (55.7 mg, 0.247 mmol), 2-cyanobenzenesulfonyl 
chloride (127 mg, 0.627 mmol), and anhydrous pyridine (50.5 µL, 0.619 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2k-o as a white solid (59.9 mg, 44% 
yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.40 (s, 1H), 10.81 (s, 1H), 8.07-8.14 (m, 2H), 8.01-8.06 (m, 4H), 
7.77-7.94 (m, 4H), 7.65 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 2.2 Hz, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.08 (dd, J = 8.7, 




was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (49.4 mg, 0.219 mmol), 3-cyanobenzenesulfonyl 
chloride (109 mg, 0.540 mmol), and anhydrous pyridine (39.0 µL, 0.478 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2k-m as an off-white solid (89.2 mg, 
73% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.05 (br s, 1H), 10.52 (br s, 1H), 8.28 (s, 1H), 8.16 (s, 1H), 
8.07-8.14 (m, 3H), 8.03 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 8.0, 1.1 Hz, 1H), 7.79 (t, J = 8.0 Hz, 1H), 7.74 (t, J = 
7.9 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.42 (d, J = 2.2 Hz, 1H), 7.32 (d, J = 8.8 Hz, 2H), 7.07 (dd, J = 8.8, 2.2 





2k-p: 4-cyano-N-(4-(5-((4-cyanophenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (44.3 mg, 0.197 mmol), 4-cyanobenzenesulfonyl 
chloride (96.0 mg, 0.476 mmol), and anhydrous pyridine (32.0 µL, 0.392 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 2k-p as a yellow-orange solid (80.3 
mg, 73% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.11 (br s, 1H), 10.60 (br s, 1H), 8.05-8.09 (m, 2H), 8.00-
8.05 (m, 4H), 7.97-8.00 (m, 2H), 7.87 (d, J = 8.5 Hz, 2H), 7.64 (d, J = 8.5 Hz, 1H), 7.41 (d, J = 1.9 Hz, 1H), 
7.31 (d, J = 8.8 Hz, 2H), 7.07 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 553.9 m/z [M-H+]-, C27H16N5O5S2 requires 




yl)phenyl)sulfamoyl)benzoate was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (55.4 mg, 0.246 
mmol), methyl-2-chlorosulfonylbenzoate (147 mg, 0.627 mmol), and anhydrous pyridine (50.0 µL, 0.613 
mmol) according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2l-o as a white solid (69.3 mg, 45% yield). 1H-NMR (500 MHz, d6-DMSO) δ 10.84 (br s, 1H), 10.29 
(br s, 1H), 8.00 (d, J = 8.8 Hz, 2H), 7.91-7.94 (m, 1H), 7.84-7.87 (m, 1H), 7.58-7.72 (m, 7H), 7.38 (d, J = 2.2 
Hz, 1H), 7.26 (d, J = 8.5 Hz, 2H), 7.08 (dd, J = 8.7, 2.0 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H); MS (ESI) 622.0 m/z 




yl)phenyl)sulfamoyl)benzoate was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (59.5 mg, 0.264 
mmol), 3-chlorosulfonicbenzoic acid methyl ester (156 mg, 0.664 mmol), and anhydrous pyridine (54.0 µL, 
0.662 mmol) according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2l-m as a white solid (121 mg, 74% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.00 (br s, 1H), 10.48 
(br s, 1H), 8.37 (d, J = 1.6 Hz, 1H), 8.30 (d, J = 1.3 Hz, 1H), 8.10-8.18 (m, 2H), 8.07 (dd, J = 7.9, 0.9 Hz, 1H), 
8.00 (d, J = 8.5 Hz, 2H), 7.91-7.95 (m, 1H), 7.73 (t, J = 7.9 Hz, 1H), 7.67 (t, J = 7.9 Hz, 1H), 7.61 (d, J = 8.8 
Hz, 1H), 7.38 (s, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.05 (dd, J = 8.7, 2.0 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H); MS 






9yl)phenyl)sulfamoyl)benzoate was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (60.8 mg, 
0.270 mmol), methyl-4-chlorosulfonylbenzoate (163 mg, 0.694 mmol), and anhydrous pyridine (55.0 µL, 0.674 
mmol) according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 2l-p as a yellow solid (19.7 mg, 20% yield). 1H-NMR (300 MHz, d6-DMSO) δ 11.05 (s, 1H), 10.51 (s, 
1H), 7.93-8.13 (m, 8H), 7.82-7.87 (m, 2H), 7.62 (d, J = 8.8 Hz, 1H), 7.39 (d, J = 2.0 Hz, 2H), 7.30 (d, J = 8.8 
Hz, 1H), 7.06 (dd, J = 8.8, 2.1 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 3H); MS (ESI) 622.2 m/z [MH+], C29H24N3O9S2 
requires 622.1; HPLC-1 = 95%; HPLC-2 = 95%. 
.................................................................................................................................................................................... 
 
2m-o: 2-(N-(4-(5-((2-carboxyphenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)sulfamoyl)benzoic acid was 
synthesized from 2l-o (147 mg, 0.236 mmol) and lithium hydroxide monohydrate (100 mg, 2.39 mmol) 
according to synthetic protocol D.  Filtration of the precipitate, followed by preparatory RP-HPLC purification, 
afforded 2m-o as a white solid (48.7 mg, 35% yield).  1H-NMR (300 MHz, d6-DMSO) δ 13.65 (br s, 1H), 10.66 
(br s, 1H), 10.05 (s, 1H), 8.00 (m, J = 8.8 Hz, 2H), 7.89 (d, J = 7.5 Hz, 1H), 7.78 (d, J = 7.5 Hz, 1H), 7.53-7.70 
(m, 7H), 7.41 (d, J = 2.0 Hz, 1H), 7.30 (m, J = 8.8 Hz, 2H), 7.10 (dd, J = 8.8, 2.1 Hz, 1H); MS (ESI) 591.8 m/z 
[M-H+]-, C27H18N3O9S2 requires 592.1; HPLC-1 = >99%; HPLC-2 = 95%. 
.................................................................................................................................................................................... 
 
2m-m: 3-(N-(4-(5-((3-carboxyphenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)sulfamoyl)benzoic acid was 
synthesized from 2l-m (76.8 mg, 0.124 mmol) and lithium hydroxide monohydrate (29.6 mg, 0.705 mmol) 
according to synthetic protocol D.  Filtration of the precipitate afforded 2m-m as a white solid (64.8 mg, 88% 
yield). 1H-NMR (500 MHz, d6-DMSO) δ 13.52 (br s, 2H), 10.99 (br s, 1H), 10.45 (s, 1H), 8.36 (t, J = 1.6 Hz, 
1H), 8.29 (t, J = 0.9 Hz, 1H), 8.15 (d, J = 7.9 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 8.00-8.07 (m, 3H), 7.91 (d, J = 
8.5 Hz, 1H), 7.71 (t, J = 7.9 Hz, 1H), 7.60-7.67 (m, 2H), 7.39 (d, J = 2.2 Hz, 1H), 7.30 (d, J = 8.8 Hz, 2H), 7.06 






2m-p: 4-(N-(4-(5-((4-carboxyphenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)sulfamoyl)benzoic acid was 
synthesized from 2l-p (316 mg, 0.508 mmol) and lithium hydroxide monohydrate (245 mg, 5.84 mmol) 
according to synthetic protocol D.  Filtration of the precipitate afforded 2m-p as a pale-yellow solid (281 mg, 
85% yield).  1H-NMR (300 MHz, d6-DMSO) δ 13.44 (br s, 2H), 11.04 (s, 1H), 10.50 (s, 1H), 8.00-8.12 (m, 6H), 
7.94 (d, J = 8.6 Hz, 2H), 7.83 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 2.0 Hz, 1H), 7.30 (d, J = 
8.8 Hz, 2H), 7.07 (dd, J = 8.8, 2.0 Hz, 1H); MS (ESI) 591.8 m/z [M-H+]-, C27H20N3O9S2 requires 592.1; HPLC-1 
= 96%; HPLC-2 = 96%. 
 
2a: N-(4-(5-(phenylsulfonamido)benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide was synthesized from 5-
amino-2-(4-aminophenyl)benzoxazole (43.1 mg, 0.191 mmol), benzenesulfonyl chloride (55.0 µL, 0.431 
mmol), and anhydrous pyridine (30.0 µL, 0.368 mmol) according to synthetic protocol A.  Flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 6 as a white solid (79.5 mg, 82% yield). 1H-
NMR (500 MHz, d6-DMSO) δ 10.90 (br s, 1H), 10.34 (br s, 1H), 8.00 (d, J = 8.8 Hz, 2H), 7.82-7.86 (m, 2H), 
7.72-7.76 (m, 2H), 7.50-7.65 (m, 7H), 7.39 (d, J = 2.2 Hz, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.07 (dd, J = 8.8, 2.2 
Hz, 1H); MS (ESI) 506.0 m/z [MH+], C25H20N3O5S2 requires 506.1; HPLC-1 = 100%; HPLC-2 = 99%. 
.................................................................................................................................................................................... 
 
3: N-(4-(5-(methylsulfonamido)benzo[d]oxazol-2-yl)phenyl)methanesulfonamide was synthesized from 5-
amino-2-(4-aminophenyl)benzoxazole (104.3 mg, 0.463 mmol), methanesulfonyl chloride (108 µL, 1.39 
mmol), and anhydrous pyridine (113 µL, 1.39 mmol) according to synthetic protocol A.  Flash chromatographic 
purification (hexanes:EtOAc gradient)  afforded 2 as a pinkish-white solid (79.1 mg, 45% yield). 1H-NMR (500 
MHz, d6-DMSO) δ 10.38 (s, 1H), 9.79 (s, 1H), 8.15 (d, J = 8.9 Hz, 1H), 7.85 (d, J = 8.7, 1H), 7.75 (d, J = 9.1 
Hz, 1H), 7.60 (d, J = 2.2 Hz, 1H), 7.40 (d, J = 8.9 Hz, 1H), 7.26 (dd, J = 8.6, 2.1 Hz, 2H), 3.33 (s, 6H); MS 
























was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole  (52.6 mg, 0.234 mmol), 
trifluoromethanesulfonic anhydride (90.0 µL, 0.535 mmol), and anhydrous pyridine (38.0 µL, 0.466 mmol) 
according to synthetic protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 3 as 
an orange solid (102 mg, 89% yield).  1H-NMR (500 MHz, d6-DMSO) δ 8.19 (d, J = 8.5 Hz, 1H), 7.85 (d, J = 
8.6 Hz, 1H), 7.67 (d, J = 2.1, 1H), 7.46 (d, J = 8.7 Hz, 2H), 7.31 (dd, J = 8.7, 2.1 Hz, 2H); MS (ESI) 490.1 m/z 
[MH+], C15H10F6N3O5S2 requires 490.0; HPLC-1 = 97%; HPLC-2 = 97%. 
.................................................................................................................................................................................... 
 
5: N-(4-(5-(propylsulfonamido)benzo[d]oxazol-2-yl)phenyl)propane-1-sulfonamide was synthesized from 
5-amino-2-(4-aminophenyl)benzoxazole (51.7 mg, 0.230 mmol), npropylsulfonyl chloride (112 µL, 0.999 
mmol), and anhydrous pyridine (76.0 µL, 0.932 mmol) according to synthetic protocol A.  Flash 
chromatographic purification (hexanes:EtOAc gradient)  afforded 4 as a white solid (59.4 mg, 59% yield). 1H-
NMR (500 MHz, d6-DMSO) δ 10.41(br s, 1H), 9.85 (br s, 1H), 8.12 (d, J = 8.2 Hz, 2H), 7.73 (d, J = 8.8 Hz, 
1H), 7.58 (d, J = 2.2 Hz, 1H), 7.39 (d, J = 8.8 Hz, 2H), 7.25 (dd, J = 8.8, 2.2 Hz, 1H), 3.16-3.24 (m, 2H), 3.04-
3.09 (m, 2H), 1.66-1.75 (m, 4H), 0.90-0.98 (m, 6H); MS (ESI) 438.2 m/z [MH+], C19H24N3O5S2 requires 438.1; 
HPLC-1 = 98%; HPLC-2 = 99%. 
.................................................................................................................................................................................... 
 
6: N-(4-(5-(thiophene-2-sulfonamido)benzo[d]oxazol-2-yl)phenyl)thiophene-2-sulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (45.0 mg, 0.200 mmol), 2-thiophenesulfonyl chloride 
(212 mg, 1.16 mmol), and anhydrous pyridine (66.0 µL, 0.810 mmol) according to synthetic protocol A.  Flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 5 as a white solid (65.6 mg, 63% yield). 1H-
NMR (500 MHz, d6-DMSO) δ 11.01 (s, 1H), 10.46 (s, 1H), 8.06 (d, J = 8.2 Hz, 2H), 7.92 (d, J = 4.7 Hz, 1H), 
7.88 (dd, J = 4.9, 1.4 Hz, 1H), 7.65-7.68 (m, 2H), 7.51 (dd, J = 3.8, 1.6 Hz, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.35 
(d, J = 8.5 Hz, 2H), 7.07-7.15 (m, 3H); MS (ESI) 517.9 m/z [MH+], C21H16N3O5S4 requires 518.0; HPLC-1 = 
















7: 1-phenyl-N-(4-(5-((phenylmethyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)methanesulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole  (41.1 mg, 0.182 mmol), ɑ-toluenesulfonyl chloride 
(145 mg, 0.759 mmol), and anhydrous pyridine (51.0 µL, 0.625 mmol) according to synthetic protocol A.  Flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 7 as a white solid (29.2 mg, 30% yield). 1H-
NMR (500 MHz, d6-DMSO) δ 10.42 (br s, 1H), 9.92 (br s, 1H), 8.10-8.14 (m, 2H), 7.73 (d, J = 8.8 Hz, 1H), 
7.59 (d, J = 1.9 Hz, 1H), 7.33-7.38 (m, 8H), 7.27-7.31 (m, 4H), 7.23 (dd, J = 8.8, 2.2 Hz, 1H), 4.60 (s, 2H), 4.49 




yl)phenyl)benzo[c][1,2,5]oxadiazole-4-sulfonamide was synthesized from 5-amino-2-(4-
aminophenyl)benzoxazole  (56.3 mg, 0.250 mmol), 2,1,3-benzoxadiazolesulfonyl chloride (119 mg, 0.546 
mmol), and anhydrous pyridine (45.0 µL, 0.552 mmol) according to synthetic protocol A.  Flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 8 as a yellow solid (115 mg, 78% yield). 1H-
NMR (500 MHz, d6-DMSO) δ 11.56 (br s, 1H), 11.00 (br s, 1H), 8.31-8.36 (m, 2H), 8.23 (d, J = 5.0 Hz, 1H), 
8.09-8.14 (m, 1H), 7.94 (d, J = 8.5 Hz, 2H), 7.70-7.75 (m, 1H), 7.65-7.69 (m, 1H), 7.56 (d, J = 8.8 Hz, 1H), 
7.40 (d, J = 1.9 Hz, 1H), 7.27 (d, J = 7.9 Hz, 2H), 7.04 (dd, J = 8.7, 2.0 Hz, 1H); MS (ESI) 590.1 m/z [MH+], 




yl)phenyl)benzo[c][1,2,5]thiadiazole-4-sulfonamide was synthesized from 5-amino-2-(4-
aminophenyl)benzoxazole  (59.7 mg, 0.265 mmol), 2,1,3-benzothiadiazole-4-sulfonyl chloride (156.5 mg, 
0.667 mmol), and anhydrous pyridine (54.0 µL, 0.662 mmol) according to synthetic protocol A.  Flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 9 as a white solid (157 mg, 95% yield). 1H-
NMR (500 MHz, d6-DMSO) δ 11.34 (br s, 1H), 10.75 (br s, 1H), 8.33-8.38 (m, 3H), 8.24 (dd, J = 7.1, 1.1 Hz, 
1H), 7.83-7.89 (m, 3H), 7.79 (dd, J = 8.8, 6.9 Hz, 1H), 7.47 (dd, J = 8.8 Hz, 1H), 7.33 (d, J = 1.9 Hz, 1H), 7.22-
7.27 (m, 2H), 7.01 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 621.9 m/z [MH+], C23H16N7O5S4 requires 622.0; HPLC-

















10: N-(4-(5-(naphthalene-1-sulfonamido)benzo[d]oxazol-2-yl)phenyl)naphthalene-1-sulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole  (54.2 mg,0.241 mmol), 1-naphthalenesulfonyl 
chloride (135 mg, 0.594 mmol), and anhydrous pyridine (45.0 µL, 0.552 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 10 as a white solid (139 mg, 95% 
yield). 1H NMR (500 MHz, DMSO) δ 11.26 (br s, 1H), 10.70 (br s, 1H), 8.73 (d, J = 8.5 Hz, 2H), 8.29 (d, J = 
7.3 Hz, 1H), 8.15-8.23 (m, 3H), 8.03-8.07 (m, 2H), 7.86 (d, J = 8.5 Hz, 2H), 7.70-7.76 (m, 2H), 7.61-7.67 (m, 
3H), 7.57 (t, J = 7.7 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.26 (d, J = 1.9 Hz, 1H), 7.18 (d, J = 8.5 Hz, 2H), 6.95 





yl)phenyl)benzo[c][1,2,5]thiadiazole-5-sulfonamide was synthesized from 5-amino-2-(4-
aminophenyl)benzoxazole  (59.1 mg, 0.262 mmol), 2,1,3-benzothiadiazole-5-sulfonyl chloride (153 mg, 0.651 
mmol), and anhydrous pyridine (53.5 µL, 0.656 mmol) according to synthetic protocol A.  Flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 11 as a yellow solid (56.6 mg, 35% yield). 1H-
NMR (500 MHz, d6-DMSO) δ 11.18 (br s, 1H), 10.68 (br s, 1H), 8.59 (s, 1H), 8.45 (dd, J = 1.9, 0.6 Hz, 1H), 
8.27-8.30 (m, 2H), 7.93-7.99 (m, 4H), 7.58 (d, J = 8.8 Hz, 1H), 7.44 (d, J = 1.9 Hz, 1H), 7.32 (d, J = 8.8 Hz, 
2H), 7.10 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 621.9 m/z [MH+], C25H16N7O5S4 requires 622.1; HPLC-1 = 98; 




was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole (57.5 mg, 0.255 mmol), 1,3-benzothazole-6-
sulfonyl chloride (148 mg, 0.634 mmol), and anhydrous pyridine (52.0 µL, 0.638 mmol) according to synthetic 
protocol A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 12 as a white solid (65.1 
mg, 41% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.01 (br s, 1H), 10.45 (br s, 1H), 9.60 (s, 1H), 9.57 (s, 1H), 
8.80 (d, J = 1.9 Hz, 1H), 8.67 (d, J = 1.6 Hz, 1H), 8.23 (d, J = 8.5 Hz, 1H), 8.21 (d, J = 9.1 Hz, 1H), 7.95-7.98 
(m, 2H), 7.92-7.95 (m, 1H), 7.84-7.88 (m, 1H), 7.57 (d, J = 8.8 Hz, 1H), 7.41 (d, J = 1.9 Hz, 1H), 7.30 (d, J = 
8.8 Hz, 2H), 7.06 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 619.8 m/z [MH+], C27H18N5O5S4 requires 620.0; HPLC-1 





13: N-(4-(5-(naphthalene-2-sulfonamido)benzo[d]oxazol-2-yl)phenyl)naphthalene-2-sulfonamide was 
synthesized from 5-amino-2-(4-aminophenyl)benzoxazole  (56.1 mg, 0.249 mmol), 2-naphthalenesulfonyl 
chloride (142 mg, 0.624 mmol), and anhydrous pyridine (51.0 µL, 0.625 mmol) according to synthetic protocol 
A.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 13 as a white solid (127 mg, 84% 
yield). 1H NMR (500 MHz, DMSO) δ 11.01 (br s, 1H), 10.43 (br s, 1H), 8.53 (s, 1H), 8.39 (s, 1H), 8.12-8.16 
(m, 1H), 8.04-8.10 (m, 3H), 7.97 (t, J = 7.9 Hz, 2H), 7.92 (d, J = 8.8 Hz, 2H), 7.80 (dd, J = 8.8, 1.9 Hz, 1H), 
7.75 (dd, J = 8.5, 1.9 Hz, 1H), 7.58-7.69 (m, 4H), 7.53 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 2.2 Hz, 1H), 7.29 (d, J = 
8.8 Hz, 2H), 7.06 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) 606.2 m/z [MH+], C33H24N3O5S2 requires 606.1; HPLC-1 




sulfonamide was synthesized from 5-amino-2-(4-aminophenyl)benzoxazole  (52.7 mg, 0.234 mmol), coumarin-
6-sulfonyl chloride (144 mg, 0.588 mmol), and anhydrous pyridine (47.5 µL, 0.582 mmol) according to 
synthetic protocol A.  Flash chromatographic purification (EtOAc:methanol gradient) afforded 14 as a tan solid 
(102 mg, 68% yield). 1H-NMR (500 MHz, d6-DMSO) δ 11.04 (br s, 1H), 10.47 (br s, 1H), 8.28 (d, J = 2.2 Hz, 
1H), 8.12-8.18 (m, 3H), 7.95-7.98 (m, 3H), 7.88 (dd, J = 8.8, 2.2 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.54 (dd, J 
= 8.5, 6.6 Hz, 2H), 7.42 (d, J = 1.9 Hz, 1H), 7.28 (d, J = 8.8 Hz, 2H), 7.06 (dd, J = 8.7, 2.0 Hz, 1H), 6.55-6.61 
(m, 2H); MS (ESI) 641.9 m/z [MH+], C31H20N3O9S2 requires 642.1; HPLC-1 = 97%; HPLC-2 = 97%. 
.................................................................................................................................................................................... 
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